You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Sciex has discontinued the Topaz platform three years after its launch while Thermo Fisher aims to drive adoption of its Cascadion following a recent US launch.
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.
The year saw the launch of high-profile platforms as well as efforts by a number of parties to streamline mass spec technologies for the clinic.
The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.
Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.
Since introducing new clinical platforms last year, Sciex has launched an automated sample prep system while Thermo Fisher has begun customer beta testing.
In the last year, both Sciex and Thermo Fisher have launched clinical platforms, but whether they will prove commercial successes remains to be seen.